These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29967617)

  • 1. TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and
    Shaikh F; He J; Bhadra P; Chen X; Siu SWI
    Front Immunol; 2018; 9():1382. PubMed ID: 29967617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
    Zou H; Li R; Hu H; Hu Y; Chen X
    Front Immunol; 2018; 9():594. PubMed ID: 29632537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4
    Islam MS; Yang Y; Chen X
    Adv Exp Med Biol; 2021; 1278():257-272. PubMed ID: 33523452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNFR2: Role in Cancer Immunology and Immunotherapy.
    Yang Y; Islam MS; Hu Y; Chen X
    Immunotargets Ther; 2021; 10():103-122. PubMed ID: 33907692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4
    He T; Liu S; Chen S; Ye J; Wu X; Bian Z; Chen X
    Front Immunol; 2018; 9():1556. PubMed ID: 30038619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy.
    Quazi S
    Med Oncol; 2022 Sep; 39(12):215. PubMed ID: 36175687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of TNFR2 agonists: a mechanistic perspective.
    Chen Y; Jiang M; Chen X
    Front Immunol; 2023; 14():1209188. PubMed ID: 37662935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2.
    Hu X; Li B; Li X; Zhao X; Wan L; Lin G; Yu M; Wang J; Jiang X; Feng W; Qin Z; Yin B; Li Z
    J Immunol; 2014 Feb; 192(3):1320-31. PubMed ID: 24379122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
    Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
    Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Therapeutic Effect of Tacrolimus in a Mouse Psoriatic Model is Associated with the Induction of Myeloid-derived Suppressor Cells.
    Chen S; Liao P; Xi L; Yang Y; Wu W; Islam MS; Lin Z; Zheng Y; Chen X
    Rheumatol Immunol Res; 2022 Dec; 3(4):190-197. PubMed ID: 36879838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Key Role of TNF-TNFR2 Interactions in the Modulation of Allergic Inflammation: A Review.
    Ahmad S; Azid NA; Boer JC; Lim J; Chen X; Plebanski M; Mohamud R
    Front Immunol; 2018; 9():2572. PubMed ID: 30473698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine.
    Faustman DL; Davis M
    Front Immunol; 2013 Dec; 4():478. PubMed ID: 24391650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response.
    Moatti A; Cohen JL
    Front Cell Dev Biol; 2021; 9():725473. PubMed ID: 34712661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
    Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
    Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperexpression of tumor necrosis factor receptor 2 inhibits differentiation of myeloid-derived suppressor cells by instigating apolarity during ageing.
    Wang M; Han Y; Yao X; Duan X; Wan J; Lou X; Yan Y; Zheng P; Wang F; Zhu L; Ni C; Pan Z; Wang Z; Chen L; Wang Z; Qin Z
    MedComm (2020); 2024 Jun; 5(6):e605. PubMed ID: 38868328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
    Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M
    Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment.
    Mohd Salim NH; Mussa A; Ahmed N; Ahmad S; Yean Yean C; Hassan R; Uskoković V; Mohamud R; Che Jalil NA
    Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNFR2: A Novel Target for Cancer Immunotherapy.
    Vanamee ÉS; Faustman DL
    Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.
    Verwoerd A; Hijdra D; Vorselaars AD; Crommelin HA; van Moorsel CH; Grutters JC; Claessen AM
    Clin Exp Immunol; 2016 Aug; 185(2):263-70. PubMed ID: 27158798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy.
    Medler J; Kucka K; Wajant H
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.